Peter A. Fasching

Goethe University Frankfurt (DE)

Research Areas

Discover Papers by Peter A. Fasching

Access 250+ million papers and cite this researcher's work with AI assistance

Try AnswerThis Free →

H-index

122

Publications

2039

Citations

78879

i10-index

706

Publications & Citations Over Time

Top Cited Publications

Want to find and read papers by this researcher? AnswerThis gives you instant access.

Title	Year	Citations
Pathological complete response and long-term clini...	2014	4596
Pembrolizumab for Early Triple-Negative Breast Can...	2020	2957
Definition and Impact of Pathologic Complete Respo...	2012	2634
Trastuzumab Emtansine for Residual Invasive HER2-P...	2018	2544
Tumour-infiltrating lymphocytes and prognosis in d...	2017	2070
Polygenic Risk Scores for Prediction of Breast Can...	2018	1154
Phase III Randomized Study of Ribociclib and Fulve...	2018	1087
Neoadjuvant carboplatin in patients with triple-ne...	2014	1019
Association between endometriosis and risk of hist...	2012	918
Common Genetic Variation In Cellular Transport Gen...	2015	906

Publications

1.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Year: 2014Citations: 4596DOI: 10.1016/s0140-6736(13)62422-8
2.
Pembrolizumab for Early Triple-Negative Breast Cancer
Year: 2020Citations: 2957DOI: 10.1056/nejmoa1910549
3.
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Year: 2012Citations: 2634DOI: 10.1200/jco.2011.38.8595
4.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Year: 2018Citations: 2544DOI: 10.1056/nejmoa1814017
5.
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Year: 2017Citations: 2070DOI: 10.1016/s1470-2045(17)30904-x
6.
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
Year: 2018Citations: 1154DOI: 10.1016/j.ajhg.2018.11.002
7.
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
Year: 2018Citations: 1087DOI: 10.1200/jco.2018.78.9909
8.
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Year: 2014Citations: 1019DOI: 10.1016/s1470-2045(14)70160-3
9.
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies
Year: 2012Citations: 918DOI: 10.1016/s1470-2045(11)70404-1
10.
Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk
Year: 2015Citations: 906DOI: 10.1371/journal.pone.0128106

About Peter A. Fasching

Peter A. Fasching is a researcher with 2039 publications and 78879 citations. They are affiliated with Goethe University Frankfurt. Their research focuses on . With an h-index of 122, they are among the top researchers in their field.

Citation Distribution

Distribution of citations across publications

Research Smarter

AnswerThis uses AI to help you search, understand, and cite research from Peter A. Fasching and 250M+ other papers.

AI-powered research assistance
Automatic citations and references
Advanced academic writing tools

Research Area Breakdown

Publication Types

Publication type data not available

Impact Metrics Over Time

Citations per publication by year